Progress in Vaccination against Cancer - 2023 (PIVAC-23)

A special issue of Onco (ISSN 2673-7523).

Deadline for manuscript submissions: 15 April 2024 | Viewed by 351

Special Issue Editors

Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece
Interests: Immune genes in tumor microenvironment; tumor antigen-specific T-cell receptor frequencies in tumor microenvironment; targeted therapies for cancer; biomarkers
Special Issues, Collections and Topics in MDPI journals
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, Athens, Greece
Interests: cancer biomarkers; regulation of adaptive antitumor immunity; immune resistance mechanisms; Immune-based therapies for cancer; cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are delighted to invite you to the next PIVAC meeting, entitled “The 23rd International Conference on Progress in Vaccination Against Cancer” (PIVAC-23), which will be held from 28th to 30th September 2023 at the Saint Savas Cancer Hospital, 171 Alexandras avenue, Athens, Greece. PIVAC-23 aims to connect scientists working in translational and clinical cancer research for three days of presentations on the most recent advances in the following fields: (i) immunotherapies (cellular, immune checkpoint blockade, vaccines); (ii) innate immunity and tumor control; (iii) host–tumor interactions in the tumor microenvironment; (iv) in vitro and in vivo models for cancer immunotherapies; (v) combinational cancer therapy approaches; and (vi) prognostic and predictive biomarkers in tumors and immune cells.

The website of PIVAC 23 is https://scep.gr/en/events/event/pivac2023/

You are cordially invited to submit your unpublished original work attending to recent advances in all aspects of computational methods related to cancer research for the following topics:

  1. cancer biomarkers for prognosis and prediction
  2. understanding TCR specificity and cross-reactivity for predicting epitope immunogenicity
  3. the tumor microenvironment and regulation of antitumor immunity
  4. immunotherapies and immune resistance
  5. cancer immunotherapies

Dr. Constantin N. Baxevanis
Dr. Sotirios P. Fortis
Dr. Maria Goulielmaki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • cancer vaccines
  • immune resistance
  • tumor microenvironment
  • biomarkers

Published Papers

This special issue is now open for submission.
Back to TopTop